Novartis weakness on Entresto patent ruling ‘seems overdone,’ says JPMorgan
The Fly

Novartis weakness on Entresto patent ruling ‘seems overdone,’ says JPMorgan

JPMorgan analyst Marjan Daeipour notes headlines out this afternoon on Novartis (NVS) losing the ‘659 patent that expires in 2025 on Entresto, noting as well that Novartis won a case against Viatris (VTRS) on the ‘938 Entresto patent that expires in 2027. The firm believes the 2027 ruling against Viatris implies that Torrent is blocked from launching their own generic and that MSN Pharma, which has a pending case on the ‘918 patent, “can’t launch either.” The firm, which also notes that Novartis indicated it will appeal the ‘659 ruling and stated that so far there are no FDA approved generics, argues that weakness in the shares on the patent loss ruling “seems overdone.” JPMorgan has a Neutral rating on Novartis shares.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on NVS:

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App